Transaction value and connected person treatment in excise valuation: proprietary concerns not inter connected undertakings, relief on valuation and c...
Appointment of Registrars as adjudicating officers under Companies Act reallocates territorial jurisdiction and sets appeal route to Regional Director...
Composite supply of drilling services and site specific chemicals characterised as composite supply; prior advance rulings set aside, tax rate left op...
Cross country pipeline classification and ITC entitlement: pipelines outside factory treated as immovable, ITC disallowed under Section 17 restriction...
Page of 4809
Press 'Enter' after typing page number.
6181 to 6200 of 96177 Results
❮
❯
❯❯
0 / 200
Expand Note
Add to Folder
No Folders have been created
+
Are you sure you want to delete "My most important" ?
Deduction for capital expenditure on scientific research under...
Pre-commencement R&D deduction denied where business had not commenced; deeming benefit requires tangible start of manufacture or commercial exploitation.
Contents
Summary
Note
Bookmark
Share
✓ Copied successfully !
Print
Print Options
For full text, please login
Login to TaxTMI
Verification Pending
The Email Id has not been verified. Click on the link we have sent on
Deduction for capital expenditure on scientific research under section 35(1)(iv) is subject to the deeming rule only where the taxpayer has in fact commenced the business that will exploit the R&D; the deeming benefit for expenditure in the three years prior hinges on an ascertainable start of manufacture or commercial exploitation. The Tribunal held that absence of purchases, sales, closing stock, and only capital work in progress and unbilled dossier revenue showed no commencement; it allowed the Revenue's appeal, reversed the CIT(A) and upheld the AO's disallowance for AY 2018 19.
Deduction for capital expenditure on scientific research under section 35(1)(iv) is subject to the deeming rule only where the taxpayer has in fact commenced the business that will exploit the R&D; the deeming benefit for expenditure in the three years prior hinges on an ascertainable start of manufacture or commercial exploitation. The Tribunal held that absence of purchases, sales, closing stock, and only capital work in progress and unbilled dossier revenue showed no commencement; it allowed the Revenue's appeal, reversed the CIT(A) and upheld the AO's disallowance for AY 2018 19.
Note: It is a system-generated summary and is for quick reference only.